NHL907 (NeuHyll)

NHL907 is an investigational fixed-dose combination (FDC) drug being developed by NeuHyll for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). The candidate combines methylphenidate, a well-established central nervous system stimulant, with viloxazine, a non-stimulant selective norepinephrine reuptake inhibitor (sNRI). This combination is designed to leverage the rapid onset of action provided by methylphenidate alongside the sustained, non-stimulant therapeutic effects of viloxazine. By utilizing two agents with complementary mechanisms, NHL907 aims to improve overall symptom control in ADHD patients while potentially allowing for lower doses of the stimulant component, thereby reducing the risk of stimulant-related side effects. As of 2024, NHL907 is in Phase 1 clinical development, with studies focusing on the safety, tolerability, and pharmacokinetics of the combination in healthy adult participants.